Business
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Ms. Dawn C. Bir to its Board of Directors (the Board). Dawn Bir is a seasoned biopharmaceutical executive and board member with a track record of contributing to the suc
About this update from Soleno Therapeutics, Inc.
[{"type":"image","alt":"Cassava Sciences, Inc.","displaySize":"","headline":null,"caption":"Cassava Sciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":169,"url":"https://media.zenfs.com/en/globenewswire.com/2dea003b4e039250b7e5acbd4c33f13e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/iA7wsdSnBGyusNcWPfyLcg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2dea003b4e039250b7e5acbd4c33f13e","width":300,"height":169}},"lazy":false},{"type":"text","content":"AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Ms. Dawn C. Bir to its Board of Directors (the Board).","length":385,"tagName":"p"},{"type":"text","content":"Dawn Bir is a seasoned biopharmaceutical executive and board member with a track record of contributing to the successful development and value creation for pre-commercial and commercial biotechnology and life science companies including Reata Pharmaceuticals, Inc. (acquired by Biogen Inc.), Geron Corporation, and Soleno Therapeutics, Inc.","length":341,"tagName":"p"},{"type":"text","content":"Claude Nicaise, MD, Chairman of the Board of Cassava shared, “We are delighted to welcome Dawn to the Board at this pivotal time for Cassava. Her commitment to building shareholder value will be a great asset to the Board and the Company, and we look forward to her contributions.”","length":281,"tagName":"p"},{"type":"text","content":"Rick Barry, President and Chief Executive Officer of Cassava commented, “As Cassava prepares to initiate our first clinical study for simufilam in TSC-related epilepsy in the first half of 2026, we believe it is important to augment our Board with additional strategic capabilities. Dawn’s track record of forging influential relationships with market stakeholders and creating a clear line of sight from the clinic to commercialization will be invaluable to Cassava as we advance the TSC-related epilepsy program.”","length":515,"tagName":"p"},{"type":"text","content":"Dawn Bir, Independent Director, Cassava noted, “The profound need to deliver a transform...